TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation for Complicated Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)~* Intolerance to ≥2 antihypertensive drug classes~* Inability to take Angiotensin-Converting-Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blockers (ARBs) or Direct Renin inhibitors (DRIs) due to planned pregnancy~* Renal artery stenosis~* Chronic Kidney Disease~Exclusion Criteria:~* renal artery anatomy ineligible for treatment~* individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit~* female participants of childbearing potential must have negative pregnancy test prior to treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Renal Denervation (Type: EXPERIMENTAL): Renal Denervation treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate adenocarcinoma (a diagnostic biopsy with at least 10 cores is needed)~* Low and intermediate-risk NCCN risk categories: low-risk ( cT1-2a, Gleason Score ≤ 6 PSA \<10 ng/ml) and among those with intermediate-risk features (clinical stage T2b-c or GS 7 or PSA 10-20 ng/ml) those patients with favorable ones (a single factor for intermediate risk and GLS 3 + 4 and \<50% of biopsy cores containing cancer) will be selected. (30).~* Age ≥18 years~* Good performance status , Eastern Cooperative Oncology Group (ECOG) \< 2) or Karnofsky performance status (KPS) \> 70~* No previous pelvic RT~* Patient not eligible to prostatectomy or patient's refusal to undergo surgery.~* NO previous prostatectomy or TURP~* Good urinary flow (peak flow ≥ 10 ml/s)~* Previous ADT is permitted~* Prostate size ≤ 60 cc~* International Prostate Symptom Score ≤ 15~* Male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Nodal involvement or distant metastases (cN1 or cM1)~* Extracapsular tumor or locally advanced disease (cT3-cT4)~* IPSS questionnaire \> 20~* Concomitant inflammatory bowel~* Prior history of chronic prostatitis~* Prior history of urethral stricture~* Important systemic diseases or oral anticoagulant therapy ongoing~* Non-conformity to dose constraints at the treatment planning~* Other invasive cancer (apart from non-melanoma skin), unless the patient has been free from disease for at least 3 years;~* Abnormal complete blood count. Any of the following: platelet count less than 75,000/ml, Hb level less than 10 gm/dl, WBC less than 3.5/ml, abnormal renal function tests (creatinine \> 1.5), severe renal impairment (GFR less than 30)~* Placement of pacemakers and metallic vascular clips (all contraindication to performing prostate mpMRI).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose external beam Radiotherapy (Type: EXPERIMENTAL): Image-guided tomotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between 18 and 70 years of age~* Planned allogeneic stem cell transplantation either from a related or an unrelated donor~* Written informed consent~Exclusion Criteria:~* Previous stem cell transplantation~* Use of antibody Campath (anti CD-52) or ATG during the conditioning~* In vitro T-cell depleted graft~* Known hypersensitivity to everolimus or other constituents of the study medication~* Symptomatic infectious disease~* Hepatic disease (ASAT \> 2 x ULN)~* Renal insufficiency (creatinine \> 2 x ULN)~* HIV infection~* Life expectancy \< 3 months~* Severe lung disease (FEV1 \< 50% of the normal value)~* Severe psychiatric disorder~* Subjects unlikely to comply with the requirements of the protocol~* Known or current alcohol, medication or drug abuse~* Pregnancy or lactation~* Women of child-bearing potential without reliable contraception unless they meet the following criteria: postmenopausal (12 months of natural amenorrhea);postoperation status (6 weeks after surgical bilateral oophorectomy with or without hysterectomy);use of highly effective birth control method (defined as one which results in a low failure rate i.e. less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomized partner)~* Men that do not use one of the following methods for prevention of conception:sexual abstinence; condom; vasectomy~* Participation of the subject in another clinical trial within the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: GIST and Memory and Attention Adaptation Training

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 and above;~2. Diagnosis of Gastrointestinal stromal tumor (GIST);~3. At least 1 year post-initiation of TKI therapy;~4. Report cognitive problems of memory and concentration attributed to GIST and/or treatment with a score of 10 or below on the FACT-Cog Impact on Quality of Life Scale;~5. Able to speak and read English;~6. Able to provide IRB-approved written informed consent; and~7. Willingness to use videoconferencing and complete phone-based neurocognitive assessments~Exclusion Criteria:~1. Previous treatment with a tyrosine kinase inhibitor medication for a non-GIST diagnosis~2. Previous CNS radiation, intrathecal therapy, or CNS-involved surgery;~3. Previous cancer history with the exception of non-melanoma skin cancer;~4. Previous exposure to chemotherapy with another cancer or due to other medical condition (e.g., methotrexate exposure for treatment of rheumatoid arthritis);~5. Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;1~6. Significant neurodevelopmental, neurobehavioral, or medical risk factors likely to affect cognitive functioning (e.g., history of neurological disorder, stroke, traumatic brain injury greater than mild severity, such as loss of consciousness \>30 minutes, medical disorder that is unstable or likely to affect cognition such as metabolic disorder, heart attack, uncontrolled diabetes or endocrine dysfunction);~7. Current severe DSM-5 mental disorder criteria, including but not limited to neurodevelopmental, substance abuse, mood, anxiety, or psychotic disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Memory and Attention Adaptation Training (MAAT) (Type: EXPERIMENTAL): A cognitive-behavioral therapy (CBT) designed for the treatment of Cancer-Related Cognitive Impairment (CRCI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven resectable adenocarcinoma of the lower oesophagus and gastric-oesophageal junction~* Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax and abdomen and ultrasound neck region. For the patients treated in this study the gastro-oesophageal junctional tumors will be staged as oesophageal tumors with respect to their lymphnode metastases.~* Age \>18y and written informed consent after at least 4 days of deliberation time from the moment the patient information has been given and has been explained.~* Weight loss \< 10% in 0.5 yr~* WHO performance status 0-1~* No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus~Exclusion Criteria:~* Previous malignancy other than basal cell carcinoma of the skin or local resection for cervical carcinoma in situ.~* Inadequate organ function as defined by:~* Inadequate haematology (Hb \< 5,5 mmol/L (red blood cell transfusions are allowed to increase the Hb at the discretion of the investigator) - neutrophils \< 1,5 109/L -platelets \<100\*109/L),~* Liver enzyme elevation (bili \> 1,5\*ULN - ASAT \> 2,5\*ULN - ALAT \> 2,5\*ULN) or~* Impaired renal function (creatinine clearance by cockcroft \< 60 cc/min)~* Proteinuria \>1,0gr/24hr~* Tumour stage: M1a and/or tumour length \> 8 cm and/or \> 5 cm radially~* Major surgery within 4 weeks prior to the start of study treatment~* Bleeding disorder~* Known allergy to one of the study drugs used~* Use of any substance known to interfere with the chemotherapy clearance~* Previous radiotherapy to the chest~* Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments~* Uncontrolled angina pectoris; cardiac failure or clinically significant arrhythmias~* Continuous use of immunosuppressive agents~* Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine~* Prior exposure to anti-EGFR targeting agents.~* Hearing loss \> 25 dB under normal~* Neurotoxicity \> CTC grade 1~* Pregnancy or breast feeding~* Patients (M/F) with reproductive potential not implementing adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-operative chemotherapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* over 18 years~* undergoing cardiac surgery~* with cardiopulmonary bypass~* bleed excessively~As it is not possible to predict in advance who will bleed, informed consent will be required for all patients over 18 who are to undergo cardiac surgery with CPB.~Will be randomized to either group~1. Those patients with diffuse bleeding after protamine administration. and / or~2. They bleed excessively after surgery. Are excessive bleeding criteria: the debit ≥ 300ml drains in the first hour; ≥ 250ml in the second hour or ≥ 150ml at any later time. Consider that the patient is bleeding excessively when the drains debit is \<150ml.~Exclusion Criteria:~* Patients \<18 years~* Extracorporeal circulation surgery~* Surgery with Mini extracorporeal circulation (MECC)~* Refuse to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group C (Type: ACTIVE_COMPARATOR): • conventional protocol, volume replacement with massive bleeding.
- Group ROTEM (Type: EXPERIMENTAL): • Protocol according to the different tests to be performed with thromboelastography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventive Strategies in Acute Respiratory Distress Syndrome (ARDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients within 12 hours after start of invasive mechanical ventilation (MV) and admitted to participating ICU (it is recommended an inclusion as soon as possible during the first 3 hours).~* LIPS \> 4 points.~* Absence of mild, moderate and severe ARDS criteria (Berlin definition).~* Older than 18 year-old.~* Signed informed consent~Exclusion Criteria:~* Bilateral pulmonary infiltrates in chest X-ray at admission.~* Mechanical ventilation \> 12 hours.~* Previous pneumonectomy or lobectomy.~* Severe cranial trauma (Glasgow Coma Scale\<9) or cranial hypertension.~* Severe chronic pulmonary disease (GOLD IV).~* Admission from other hospital under MV.~* Limitation of therapeutic effort.~* Pregnancy.~* Acute pulmonary embolism.~* Participation in other interventional trials.~* Previous randomized in the proposed trial.~* Absence of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Protective ventilation arm (Type: EXPERIMENTAL): * Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)~* Plateau pressure less than 25 centimeter of water (cmH2O)~* Minimum PEEP of 5 cmH2O.
- Control group (Type: ACTIVE_COMPARATOR): Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)~* Plateau pressure less than 25 cmH2O~* Minimum PEEP of 5 cmH2O.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Viral Etiology of Severe Acute Respiratory InFection in CriticallY Ill Patients Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥14 years old) patients~* A clinical presentation consistent with community-acquired SARI/pneumonia~* AND admitted to the ICU because of respiratory failure or sepsis~* AND is invasively mechanically ventilated.~Exclusion Criteria:~* Diagnosed with COVID-19~* Duration of illness \> 14 days since symptom onset~* Did not meet inclusion criteria in the first 48 hrs of admission to the ICU.~* Patient already enrolled in the study~* Participant or legal guardian refuses to participate in the study.~* Diagnosis is not related to SARI~* Enrolled in interventional trial of investigational therapeutics for pneumonia.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Severe Acute Respiratory Infection (SARI) (Type: None): Nasopharyngeal swab, MINI BAL samples, Serum samples, Plasma sample, and Blood sample (RNA) will be collected from patients on day 0 (baseline) of enrollment, and on day 14 of enrollment.~SAMPLING PROCEDURES:~1. Nucleic acid extraction~2. Polymerase chain reaction (PCR) 2.1 Testing for MERS-CoV will be performed by RT-PCR 2.2 We will test for Infleunza H and N PCR for influenza H 2.3 We will also test for a panel of viruses using PCR multiplex that includes influenza A ; influenza B ; influenza C ; influenza A (H1N1) swl ; parainfluenza viruses 1, 2, 3 and 4 ; coronaviruses NL63, 229E, OC43 and HKU1; human metapneumoviruses A/B; rhinovirus ;respiratory syncytial viruses A and B; adenovirus; enterovirus; parechovirus; bocavirus.~3.16S PCR and sanger sequencing for bacterial detection 4.Metagenomics /Next Generation Sequencing 5.Microbiome bioinformatics analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Disseminating a Waitlist Treatment for Anxiety With Velibra

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently on the Anxiety and Stress Clinic waitlist~* At least 18 years old~* Fluent in English~* Have access to a computer or web device~Exclusion Criteria:~* Active suicidal ideation with intent to harm oneself in the past week (e.g., endorses Yes toC-SSRS item 4 or higher).~* A formal diagnosis of Bipolar I disorder without current utilization of stabilizing medications.~* Present or past psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Velibra (Type: EXPERIMENTAL): All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Brain Computer Interfaces (Mu Rhythm Learning)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* Able to read text on a computer screen~* Able to understand and remember instructions concerning participation~Exclusion Criteria:~* Unable give informed consent.~* Unable to understand and follow instructions.~* Have abnormal tone or uncontrolled movements in the head-and-neck that would interfere with EEG recordings.~* Known to have photosensitive epilepsy.~* Open head lesions or sores

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Performance Study of SONA Saliva C-19 Rapid Test

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Up to 500 subjects will be screened, consented, and enrolled to obtain a minimum of 50 eligible candidates. In order to be eligible to participate in this study, an individual must meet all of the following criteria:~1. Presenting to the Emergency Department at HRH.~2. Receiving a COVID-19 RT-PCR test as per standard pathway of care.~3. Provide written informed consent.~4. Patients must be presenting or have experienced at least one (1) or more signs or symptoms of COVID-19 within ≤ 7 days:~   1. Fever as self-described or measured ≥ 38 °C (100.4°F)~  2. Chills~  3. Cough~  4. Shortness of breath~  5. Congestion or runny nose~  6. Difficulty Breathing~  7. Muscle or Body Aches~  8. Vomiting~  9. Diarrhea~  10. New loss of sense of taste or smell~  11. Headache~  12. General malaise~  13. Sore Throat~Exclusion Criteria:~1. Asymptomatic patients.~2. Patients unable to provide a saliva sample.~3. Patients unable to give consent.~4. Patients who will not be receiving a nasopharyngeal RT-PCR test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SARS_CoV_2 Antigen Rapid Test (Type: EXPERIMENTAL): The same group of patients participated in two arms of the study:~One arm was for obtaining performance data of the Sona Saliva C-19 Rapid test and the comparator arm was to obtain data from the primary care route using approved RT-PCR testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti Vitamin K Therapeutic Education

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age from 0 to 18 years~* AVK prescription~* to accept participating to AVK therapeutic education program~* informed consent form of parents or legal person~Exclusion Criteria:~* parents or legal person refusal to enter in the AVK therapeutic education

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- AVK (Type: None): patient with AVK treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues